Erzincan Binali Yıldırım ÜniversitesiErzincan Binali Yıldırım ÜniversitesiAçık Erişim Arşivi · RDL Open

Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper

Review ArticleAçık Erişim

Özet

Breast cancer is the most common type of cancer affecting women worldwide and its risk increases with age. Compared with other breast cancer subtypes, triple negative breast cancer (TNBC) behaves more aggressively, with earlier relapses and poorer survival outcomes. Although the incidence of TNBC decreases with age, it still affects about 10% of older women with breast cancer. The management of TNBC in older patients is particularly challenging as chemotherapy is the main treatment choice in both early and advanced diseases and older patients are often prone to increased treatment-related toxicities. This review highlights the specific considerations in this vulnerable group of patients and summarizes the current evidence for TNBC management in older adults from early to late stage of disease. © 2022 Elsevier Ltd

Anahtar Kelimeler

AssessmentChemotherapyGeriatric assessmentImmunotherapyOlder patientsTriple negative breast cancerAgedFemaleHumansTriple Negative Breast Neoplasmsanthracyclineatezolizumabcapecitabinecarboplatincyclophosphamidedoxorubicindurvalumaberibulingemcitabineimmune checkpoint inhibitorixabepilonenicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitorolaparibpaclitaxelpembrolizumabsacituzumab govitecantalazoparibtaxane derivativeveliparibvinorelbine tartrate
RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/12712Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1016/j.jgo.2022.01.002Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorChan, Wing-Lok
dc.contributor.authorMarinho, Joana
dc.contributor.authorChavarri-Guerra, Yanin
dc.contributor.authorHincapie-Echeverri, Jacobo
dc.contributor.authorVelasco, Rogelio N.
dc.contributor.authorAkagunduz, Baran
dc.contributor.authorRoy, Mukul
dc.contributor.authorKwong, Wing Tung Gobby
dc.contributor.authorWu, Wing-Fong
dc.contributor.authorBattisti, Nicolò Matteo Luca
dc.contributor.authorSoto-Perez-de-Celis, Enrique
dc.date.accessioned2026-10-18T20:27:34.998596615Z
dc.date.available2026-10-18T20:27:34.998596615Z
dc.date.issued2022
dc.description.abstractBreast cancer is the most common type of cancer affecting women worldwide and its risk increases with age. Compared with other breast cancer subtypes, triple negative breast cancer (TNBC) behaves more aggressively, with earlier relapses and poorer survival outcomes. Although the incidence of TNBC decreases with age, it still affects about 10% of older women with breast cancer. The management of TNBC in older patients is particularly challenging as chemotherapy is the main treatment choice in both early and advanced diseases and older patients are often prone to increased treatment-related toxicities. This review highlights the specific considerations in this vulnerable group of patients and summarizes the current evidence for TNBC management in older adults from early to late stage of disease. © 2022 Elsevier Ltd
dc.identifier.doi10.1016/j.jgo.2022.01.002
dc.identifier.endpage571
dc.identifier.issn1879-4068
dc.identifier.issue5
dc.identifier.pmid35078741
dc.identifier.scopus2-s2.0-85123352365
dc.identifier.startpage563
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/12712
dc.identifier.volume13
dc.language.isoen
dc.publisherElsevier Ltd
dc.relation.ispartofJournal of Geriatric Oncology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAssessment
dc.subjectChemotherapy
dc.subjectGeriatric assessment
dc.subjectImmunotherapy
dc.subjectOlder patients
dc.subjectTriple negative breast cancer
dc.subjectAged
dc.subjectFemale
dc.subjectHumans
dc.subjectTriple Negative Breast Neoplasms
dc.subjectanthracycline
dc.subjectatezolizumab
dc.subjectcapecitabine
dc.subjectcarboplatin
dc.subjectcyclophosphamide
dc.subjectdoxorubicin
dc.subjectdurvalumab
dc.subjecteribulin
dc.subjectgemcitabine
dc.subjectimmune checkpoint inhibitor
dc.subjectixabepilone
dc.subjectnicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor
dc.subjectolaparib
dc.subjectpaclitaxel
dc.subjectpembrolizumab
dc.subjectsacituzumab govitecan
dc.subjecttalazoparib
dc.subjecttaxane derivative
dc.subjectveliparib
dc.subjectvinorelbine tartrate
dc.titleSystemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper
dc.typeReview Article
dspace.entity.typePublication
rdl.citation.scopus8
rdl.departmentDepartment of Medical Oncology, Erzincan Binali Yildirim University Medical School, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexPUBMED